APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neuroendocrine Carcinoma

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Neuroendocrine Carcinoma Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025194 pages

Choose your research edition.

Industry ResearchNeuroendocrine Carcinoma Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Neuroendocrine Carcinoma Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Neuroendocrine Carcinoma Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neuroendocrine Carcinoma Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Neuroendocrine Carcinoma Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Neuroendocrine Carcinoma market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for Neuroendocrine Carcinoma is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Neuroendocrine Carcinoma is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Neuroendocrine Carcinoma is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Neuroendocrine Carcinoma is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Neuroendocrine Carcinoma include Teva, Novartis, Pfizer, Abbvie, Valeant, Mateon, Lexicon, Jubilant and Ipsen, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global Neuroendocrine Carcinoma market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Neuroendocrine Carcinoma and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Neuroendocrine Carcinoma revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Neuroendocrine Carcinoma market size, projected growth trends, production technologies, key applications, and end-use industries.

Neuroendocrine Carcinoma Segment by Company

Teva

Novartis

Pfizer

Abbvie

Valeant

Mateon

Lexicon

Jubilant

Ipsen

F.Hoffmann-La Roche

Chiasma

Advanced Accelerator

Neuroendocrine Carcinoma Segment by Type

Somatostatin Analogs

Chemotherapy

Targeted Therapy

Neuroendocrine Carcinoma Segment by Application

Oncology Centres

Clinics

Hospital

Ambulatory Surgery Centres

Neuroendocrine Carcinoma Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuroendocrine Carcinoma market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neuroendocrine Carcinoma and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuroendocrine Carcinoma.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Neuroendocrine Carcinoma in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Neuroendocrine Carcinoma industry.

Chapter 3: Detailed analysis of Neuroendocrine Carcinoma companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Neuroendocrine Carcinomarevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Neuroendocrine Carcinoma Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Somatostatin Analogs Table 3. Key Players of Chemotherapy Table 4. Key Players of Targeted Therapy Table 4. Global Neuroendocrine Carcinoma Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 5. Key Players of Oncology Centres Table 6. Key Players of Clinics Table 7. Key Players of Hospital Table 8. Key Players of Ambulatory Surgery Centres Table 9. Global Neuroendocrine Carcinoma Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 10. Global Neuroendocrine Carcinoma Market Size by Region (2021-2026) & (US$ Million) Table 11. Global Neuroendocrine Carcinoma Market Share by Region (2021-2026) Table 12. Global Neuroendocrine Carcinoma Market Size by Region (2027-2032) & (US$ Million) Table 13. Global Neuroendocrine Carcinoma Market Share by Region (2027-2032) Table 14. Neuroendocrine Carcinoma Industry Trends Table 15. Neuroendocrine Carcinoma Industry Drivers Table 16. Neuroendocrine Carcinoma Industry Opportunities and Challenges Table 17. Neuroendocrine Carcinoma Industry Restraints Table 18. Global Neuroendocrine Carcinoma Revenue by Company (US$ Million) & (2021-2026) Table 19. Global Neuroendocrine Carcinoma Revenue Market Share by Company (2021-2026) Table 20. Global Neuroendocrine Carcinoma Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 21. Global Neuroendocrine Carcinoma Key Company Head Office and Area Served Table 22. Global Neuroendocrine Carcinoma Company, Product Type & Application Table 23. Global Neuroendocrine Carcinoma Company Establishment Date Table 24. Global Company Market Concentration Ratio (CR5 and HHI) Table 25. Global Neuroendocrine Carcinoma by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 26. Global Neuroendocrine Carcinoma Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Neuroendocrine Carcinoma Market Size by Type (2021-2026) & (US$ Million) Table 28. Global Neuroendocrine Carcinoma Market Size by Type (2027-2032) & (US$ Million) Table 29. Global Neuroendocrine Carcinoma Revenue Market Share by Type (2021-2026) Table 30. Global Neuroendocrine Carcinoma Revenue Market Share by Type (2027-2032) Table 31. Global Neuroendocrine Carcinoma Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Neuroendocrine Carcinoma Market Size by Application (2021-2026) & (US$ Million) Table 33. Global Neuroendocrine Carcinoma Market Size by Application (2027-2032) & (US$ Million) Table 34. Global Neuroendocrine Carcinoma Revenue Market Share by Application (2021-2026) Table 35. Global Neuroendocrine Carcinoma Revenue Market Share by Application (2027-2032) Table 36. Teva Company Information Table 37. Teva Business Overview Table 38. Teva Neuroendocrine Carcinoma Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Teva Neuroendocrine Carcinoma Product Portfolio Table 40. Teva Recent Development Table 41. Novartis Company Information Table 42. Novartis Business Overview Table 43. Novartis Neuroendocrine Carcinoma Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Novartis Neuroendocrine Carcinoma Product Portfolio Table 45. Novartis Recent Development Table 46. Pfizer Company Information Table 47. Pfizer Business Overview Table 48. Pfizer Neuroendocrine Carcinoma Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Pfizer Neuroendocrine Carcinoma Product Portfolio Table 50. Pfizer Recent Development Table 51. Abbvie Company Information Table 52. Abbvie Business Overview Table 53. Abbvie Neuroendocrine Carcinoma Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Abbvie Neuroendocrine Carcinoma Product Portfolio Table 55. Abbvie Recent Development Table 56. Valeant Company Information Table 57. Valeant Business Overview Table 58. Valeant Neuroendocrine Carcinoma Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Valeant Neuroendocrine Carcinoma Product Portfolio Table 60. Valeant Recent Development Table 61. Mateon Company Information Table 62. Mateon Business Overview Table 63. Mateon Neuroendocrine Carcinoma Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Mateon Neuroendocrine Carcinoma Product Portfolio Table 65. Mateon Recent Development Table 66. Lexicon Company Information Table 67. Lexicon Business Overview Table 68. Lexicon Neuroendocrine Carcinoma Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Lexicon Neuroendocrine Carcinoma Product Portfolio Table 70. Lexicon Recent Development Table 71. Jubilant Company Information Table 72. Jubilant Business Overview Table 73. Jubilant Neuroendocrine Carcinoma Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Jubilant Neuroendocrine Carcinoma Product Portfolio Table 75. Jubilant Recent Development Table 76. Ipsen Company Information Table 77. Ipsen Business Overview Table 78. Ipsen Neuroendocrine Carcinoma Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Ipsen Neuroendocrine Carcinoma Product Portfolio Table 80. Ipsen Recent Development Table 81. F.Hoffmann-La Roche Company Information Table 82. F.Hoffmann-La Roche Business Overview Table 83. F.Hoffmann-La Roche Neuroendocrine Carcinoma Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. F.Hoffmann-La Roche Neuroendocrine Carcinoma Product Portfolio Table 85. F.Hoffmann-La Roche Recent Development Table 86. Chiasma Company Information Table 87. Chiasma Business Overview Table 88. Chiasma Neuroendocrine Carcinoma Revenue and Gross Margin (US$ Million) & (2021-2026) Table 89. Chiasma Neuroendocrine Carcinoma Product Portfolio Table 90. Chiasma Recent Development Table 91. Advanced Accelerator Company Information Table 92. Advanced Accelerator Business Overview Table 93. Advanced Accelerator Neuroendocrine Carcinoma Revenue and Gross Margin (US$ Million) & (2021-2026) Table 94. Advanced Accelerator Neuroendocrine Carcinoma Product Portfolio Table 95. Advanced Accelerator Recent Development Table 96. North America Neuroendocrine Carcinoma Market Size by Type (2021-2026) & (US$ Million) Table 97. North America Neuroendocrine Carcinoma Market Size by Type (2027-2032) & (US$ Million) Table 98. North America Neuroendocrine Carcinoma Market Size by Application (2021-2026) & (US$ Million) Table 99. North America Neuroendocrine Carcinoma Market Size by Application (2027-2032) & (US$ Million) Table 100. North America Neuroendocrine Carcinoma Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 101. North America Neuroendocrine Carcinoma Market Size by Country (2021-2026) Table 102. North America Neuroendocrine Carcinoma Market Size by Country (2027-2032) Table 103. Europe Neuroendocrine Carcinoma Market Size by Type (2021-2026) & (US$ Million) Table 104. Europe Neuroendocrine Carcinoma Market Size by Type (2027-2032) & (US$ Million) Table 105. Europe Neuroendocrine Carcinoma Market Size by Application (2021-2026) & (US$ Million) Table 106. Europe Neuroendocrine Carcinoma Market Size by Application (2027-2032) & (US$ Million) Table 107. Europe Neuroendocrine Carcinoma Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 108. Europe Neuroendocrine Carcinoma Market Size by Country (2021-2026) Table 109. Europe Neuroendocrine Carcinoma Market Size by Country (2027-2032) Table 110. China Neuroendocrine Carcinoma Market Size by Type (2021-2026) & (US$ Million) Table 111. China Neuroendocrine Carcinoma Market Size by Type (2027-2032) & (US$ Million) Table 112. China Neuroendocrine Carcinoma Market Size by Application (2021-2026) & (US$ Million) Table 113. China Neuroendocrine Carcinoma Market Size by Application (2027-2032) & (US$ Million) Table 114. Asia Neuroendocrine Carcinoma Market Size by Type (2021-2026) & (US$ Million) Table 115. Asia Neuroendocrine Carcinoma Market Size by Type (2027-2032) & (US$ Million) Table 116. Asia Neuroendocrine Carcinoma Market Size by Application (2021-2026) & (US$ Million) Table 117. Asia Neuroendocrine Carcinoma Market Size by Application (2027-2032) & (US$ Million) Table 118. Asia Neuroendocrine Carcinoma Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 119. Asia Neuroendocrine Carcinoma Market Size by Country (2021-2026) Table 120. Asia Neuroendocrine Carcinoma Market Size by Country (2027-2032) Table 121. South America, Middle East & Africa Neuroendocrine Carcinoma Market Size by Type (2021-2026) & (US$ Million) Table 122. South America, Middle East & Africa Neuroendocrine Carcinoma Market Size by Type (2027-2032) & (US$ Million) Table 123. South America, Middle East & Africa Neuroendocrine Carcinoma Market Size by Application (2021-2026) & (US$ Million) Table 124. South America, Middle East & Africa Neuroendocrine Carcinoma Market Size by Application (2027-2032) & (US$ Million) Table 125. South America, Middle East & Africa Neuroendocrine Carcinoma Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 126. South America, Middle East & Africa Neuroendocrine Carcinoma Market Size by Country (2021-2026) Table 127. South America, Middle East & Africa Neuroendocrine Carcinoma Market Size by Country (2027-2032) Table 128. Research Programs/Design for This Report Table 129. Authors List of This Report Table 130. Secondary Sources Table 131. Primary Sources List of Figures Figure 1. Neuroendocrine Carcinoma Product Image Figure 2. Global Neuroendocrine Carcinoma Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Neuroendocrine Carcinoma Market Share by Type: 2025 VS 2032 Figure 4. Somatostatin Analogs Image Figure 5. Chemotherapy Image Figure 6. Targeted Therapy Image Figure 7. Global Neuroendocrine Carcinoma Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 8. Global Neuroendocrine Carcinoma Market Share by Application: 2025 VS 2032 Figure 9. Oncology Centres Image Figure 10. Clinics Image Figure 11. Hospital Image Figure 12. Ambulatory Surgery Centres Image Figure 13. Global Neuroendocrine Carcinoma Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Neuroendocrine Carcinoma Market Size (2021-2032) & (US$ Million) Figure 15. Global Neuroendocrine Carcinoma Market Share by Region: 2025 VS 2032 Figure 16. Years Considered Figure 17. Global Neuroendocrine Carcinoma Market Share by Players in 2025 Figure 18. Global Top 5 and 10 Neuroendocrine Carcinoma Players Market Share by Revenue in 2025 Figure 19. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global Neuroendocrine Carcinoma Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Neuroendocrine Carcinoma Revenue Market Share by Type (2021-2032) Figure 22. Global Neuroendocrine Carcinoma Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Neuroendocrine Carcinoma Revenue Market Share by Application (2021-2032) Figure 24. North America Neuroendocrine Carcinoma Market Size (2021-2032) & (US$ Million) Figure 25. North America Neuroendocrine Carcinoma Market Share by Type (2021-2032) Figure 26. North America Neuroendocrine Carcinoma Market Share by Application (2021-2032) Figure 27. North America Neuroendocrine Carcinoma Market Share by Country (2021-2032) Figure 28. United States Neuroendocrine Carcinoma Market Size (2021-2032) & (US$ Million) Figure 29. Canada Neuroendocrine Carcinoma Market Size (2021-2032) & (US$ Million) Figure 30. Mexico Neuroendocrine Carcinoma Market Size (2021-2032) & (US$ Million) Figure 31. Europe Neuroendocrine Carcinoma Market Size (2021-2032) & (US$ Million) Figure 32. Europe Neuroendocrine Carcinoma Market Share by Type (2021-2032) Figure 33. Europe Neuroendocrine Carcinoma Market Share by Application (2021-2032) Figure 34. Europe Neuroendocrine Carcinoma Market Share by Country (2021-2032) Figure 35. Germany Neuroendocrine Carcinoma Market Size (2021-2032) & (US$ Million) Figure 36. France Neuroendocrine Carcinoma Market Size (2021-2032) & (US$ Million) Figure 37. U.K. Neuroendocrine Carcinoma Market Size (2021-2032) & (US$ Million) Figure 38. Italy Neuroendocrine Carcinoma Market Size (2021-2032) & (US$ Million) Figure 39. Russia Neuroendocrine Carcinoma Market Size (2021-2032) & (US$ Million) Figure 40. Nordic Countries Neuroendocrine Carcinoma Market Size (2021-2032) & (US$ Million) Figure 41. China Neuroendocrine Carcinoma Market Size (2021-2032) & (US$ Million) Figure 42. China Neuroendocrine Carcinoma Market Share by Type (2021-2032) Figure 43. China Neuroendocrine Carcinoma Market Share by Application (2021-2032) Figure 44. Asia Neuroendocrine Carcinoma Market Size (2021-2032) & (US$ Million) Figure 45. Asia Neuroendocrine Carcinoma Market Share by Type (2021-2032) Figure 46. Asia Neuroendocrine Carcinoma Market Share by Application (2021-2032) Figure 47. Asia Neuroendocrine Carcinoma Market Share by Country (2021-2032) Figure 48. Japan Neuroendocrine Carcinoma Market Size (2021-2032) & (US$ Million) Figure 49. South Korea Neuroendocrine Carcinoma Market Size (2021-2032) & (US$ Million) Figure 50. Taiwan Neuroendocrine Carcinoma Market Size (2021-2032) & (US$ Million) Figure 51. Southeast Asia Neuroendocrine Carcinoma Market Size (2021-2032) & (US$ Million) Figure 52. India Neuroendocrine Carcinoma Market Size (2021-2032) & (US$ Million) Figure 53. Australia Neuroendocrine Carcinoma Market Size (2021-2032) & (US$ Million) Figure 54. South America, Middle East & Africa Neuroendocrine Carcinoma Market Size (2021-2032) & (US$ Million) Figure 55. South America, Middle East & Africa Neuroendocrine Carcinoma Market Share by Type (2021-2032) Figure 56. South America, Middle East & Africa Neuroendocrine Carcinoma Market Share by Application (2021-2032) Figure 57. South America, Middle East & Africa Neuroendocrine Carcinoma Market Share by Country (2021-2032) Figure 58. Brazil Neuroendocrine Carcinoma Market Size (2021-2032) & (US$ Million) Figure 59. South Africa Neuroendocrine Carcinoma Market Size (2021-2032) & (US$ Million) Figure 60. Saudi Arabia Neuroendocrine Carcinoma Market Size (2021-2032) & (US$ Million) Figure 61. Turkey Neuroendocrine Carcinoma Market Size (2021-2032) & (US$ Million) Figure 62. Argentina Neuroendocrine Carcinoma Market Size (2021-2032) & (US$ Million) Figure 63. UAE Neuroendocrine Carcinoma Market Size (2021-2032) & (US$ Million) Figure 64. Egypt Neuroendocrine Carcinoma Market Size (2021-2032) & (US$ Million) Figure 65. Chile Neuroendocrine Carcinoma Market Size (2021-2032) & (US$ Million) Figure 66. Research Process Figure 67. Key Executives Interviewed

Scope & coverage.

Types
  • Somatostatin Analogs
  • Chemotherapy
  • Targeted Therapy
Applications
  • Oncology Centres
  • Clinics
  • Hospital
  • Ambulatory Surgery Centres
Companies covered
  • Teva
  • Novartis
  • Pfizer
  • Abbvie
  • Valeant
  • Mateon
  • Lexicon
  • Jubilant
  • Ipsen
  • F.Hoffmann-La Roche
  • Chiasma
  • Advanced Accelerator

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Neuroendocrine Carcinoma Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Somatostatin Analogs
  5. 1.2.3 Chemotherapy
  6. 1.2.4 Targeted Therapy
  7. 1.3 Market Analysis by Application
  8. 1.3.1 Global Neuroendocrine Carcinoma Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  9. 1.3.2 Oncology Centres
  10. 1.3.3 Clinics
  11. 1.3.4 Hospital
  12. 1.3.5 Ambulatory Surgery Centres
  13. 1.4 Global Market Growth Prospects
  14. 1.5 Global Neuroendocrine Carcinoma Growth Trends by Region
  15. 1.5.1 Global Neuroendocrine Carcinoma Market Size by Region: 2021 VS 2025 VS 2032
  16. 1.5.2 Neuroendocrine Carcinoma Market Size by Region (2021-2026)
  17. 1.5.3 Neuroendocrine Carcinoma Market Size by Region (2027-2032)
  18. 1.6 Assumptions and Limitations
  19. 1.7 Study Goals and Objectives
  20. 1.8 Years Considered
2 Global Neuroendocrine Carcinoma Market Dynamics
  1. 2.1 Neuroendocrine Carcinoma Industry Trends
  2. 2.2 Neuroendocrine Carcinoma Industry Drivers
  3. 2.3 Neuroendocrine Carcinoma Industry Opportunities and Challenges
  4. 2.4 Neuroendocrine Carcinoma Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Neuroendocrine Carcinoma Revenue by Company (2021-2026)
  2. 3.2 Global Neuroendocrine Carcinoma Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Neuroendocrine Carcinoma Key Company Head office and Area Served
  4. 3.4 Global Neuroendocrine Carcinoma Company, Product Type & Application
  5. 3.5 Global Neuroendocrine Carcinoma Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Neuroendocrine Carcinoma Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Neuroendocrine Carcinoma Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Neuroendocrine Carcinoma Tier 1, Tier 2, and Tier 3
4 Neuroendocrine Carcinoma Market by Type
  1. 4.1 Global Neuroendocrine Carcinoma Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Neuroendocrine Carcinoma Market Size by Type (2021-2032)
  3. 4.3 Global Neuroendocrine Carcinoma Market Size Share by Type (2021-2032)
5 Neuroendocrine Carcinoma Market by Application
  1. 5.1 Global Neuroendocrine Carcinoma Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Neuroendocrine Carcinoma Market Size by Application (2021-2032)
  3. 5.3 Global Neuroendocrine Carcinoma Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Teva
  2. 6.1.1 Teva Company Information
  3. 6.1.2 Teva Business Overview
  4. 6.1.3 Teva Neuroendocrine Carcinoma Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Teva Neuroendocrine Carcinoma Product Portfolio
  6. 6.1.5 Teva Recent Developments
  7. 6.2 Novartis
  8. 6.2.1 Novartis Company Information
  9. 6.2.2 Novartis Business Overview
  10. 6.2.3 Novartis Neuroendocrine Carcinoma Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Novartis Neuroendocrine Carcinoma Product Portfolio
  12. 6.2.5 Novartis Recent Developments
  13. 6.3 Pfizer
  14. 6.3.1 Pfizer Company Information
  15. 6.3.2 Pfizer Business Overview
  16. 6.3.3 Pfizer Neuroendocrine Carcinoma Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Pfizer Neuroendocrine Carcinoma Product Portfolio
  18. 6.3.5 Pfizer Recent Developments
  19. 6.4 Abbvie
  20. 6.4.1 Abbvie Company Information
  21. 6.4.2 Abbvie Business Overview
  22. 6.4.3 Abbvie Neuroendocrine Carcinoma Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Abbvie Neuroendocrine Carcinoma Product Portfolio
  24. 6.4.5 Abbvie Recent Developments
  25. 6.5 Valeant
  26. 6.5.1 Valeant Company Information
  27. 6.5.2 Valeant Business Overview
  28. 6.5.3 Valeant Neuroendocrine Carcinoma Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Valeant Neuroendocrine Carcinoma Product Portfolio
  30. 6.5.5 Valeant Recent Developments
  31. 6.6 Mateon
  32. 6.6.1 Mateon Company Information
  33. 6.6.2 Mateon Business Overview
  34. 6.6.3 Mateon Neuroendocrine Carcinoma Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 Mateon Neuroendocrine Carcinoma Product Portfolio
  36. 6.6.5 Mateon Recent Developments
  37. 6.7 Lexicon
  38. 6.7.1 Lexicon Company Information
  39. 6.7.2 Lexicon Business Overview
  40. 6.7.3 Lexicon Neuroendocrine Carcinoma Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 Lexicon Neuroendocrine Carcinoma Product Portfolio
  42. 6.7.5 Lexicon Recent Developments
  43. 6.8 Jubilant
  44. 6.8.1 Jubilant Company Information
  45. 6.8.2 Jubilant Business Overview
  46. 6.8.3 Jubilant Neuroendocrine Carcinoma Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 Jubilant Neuroendocrine Carcinoma Product Portfolio
  48. 6.8.5 Jubilant Recent Developments
  49. 6.9 Ipsen
  50. 6.9.1 Ipsen Company Information
  51. 6.9.2 Ipsen Business Overview
  52. 6.9.3 Ipsen Neuroendocrine Carcinoma Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 Ipsen Neuroendocrine Carcinoma Product Portfolio
  54. 6.9.5 Ipsen Recent Developments
  55. 6.10 F.Hoffmann-La Roche
  56. 6.10.1 F.Hoffmann-La Roche Company Information
  57. 6.10.2 F.Hoffmann-La Roche Business Overview
  58. 6.10.3 F.Hoffmann-La Roche Neuroendocrine Carcinoma Revenue and Gross Margin (US$ Million) & (2021-2026)
  59. 6.10.4 F.Hoffmann-La Roche Neuroendocrine Carcinoma Product Portfolio
  60. 6.10.5 F.Hoffmann-La Roche Recent Developments
  61. 6.11 Chiasma
  62. 6.11.1 Chiasma Company Information
  63. 6.11.2 Chiasma Business Overview
  64. 6.11.3 Chiasma Neuroendocrine Carcinoma Revenue and Gross Margin (US$ Million) & (2021-2026)
  65. 6.11.4 Chiasma Neuroendocrine Carcinoma Product Portfolio
  66. 6.11.5 Chiasma Recent Developments
  67. 6.12 Advanced Accelerator
  68. 6.12.1 Advanced Accelerator Company Information
  69. 6.12.2 Advanced Accelerator Business Overview
  70. 6.12.3 Advanced Accelerator Neuroendocrine Carcinoma Revenue and Gross Margin (US$ Million) & (2021-2026)
  71. 6.12.4 Advanced Accelerator Neuroendocrine Carcinoma Product Portfolio
  72. 6.12.5 Advanced Accelerator Recent Developments
7 North America
  1. 7.1 North America Neuroendocrine Carcinoma Market Size (2021-2032)
  2. 7.2 North America Neuroendocrine Carcinoma Market Size by Type
  3. 7.2.1 North America Neuroendocrine Carcinoma Market Size by Type (2021-2026)
  4. 7.2.2 North America Neuroendocrine Carcinoma Market Size by Type (2027-2032)
  5. 7.2.3 North America Neuroendocrine Carcinoma Market Share by Type (2021-2032)
  6. 7.3 North America Neuroendocrine Carcinoma Market Size by Application
  7. 7.3.1 North America Neuroendocrine Carcinoma Market Size by Application (2021-2026)
  8. 7.3.2 North America Neuroendocrine Carcinoma Market Size by Application (2027-2032)
  9. 7.3.3 North America Neuroendocrine Carcinoma Market Share by Application (2021-2032)
  10. 7.4 North America Neuroendocrine Carcinoma Market Size by Country
  11. 7.4.1 North America Neuroendocrine Carcinoma Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Neuroendocrine Carcinoma Market Size by Country (2021-2026)
  13. 7.4.3 North America Neuroendocrine Carcinoma Market Size by Country (2027-2032)
  14. 7.4.4 North America Neuroendocrine Carcinoma Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Neuroendocrine Carcinoma Market Size (2021-2032)
  2. 8.2 Europe Neuroendocrine Carcinoma Market Size by Type
  3. 8.2.1 Europe Neuroendocrine Carcinoma Market Size by Type (2021-2026)
  4. 8.2.2 Europe Neuroendocrine Carcinoma Market Size by Type (2027-2032)
  5. 8.2.3 Europe Neuroendocrine Carcinoma Market Share by Type (2021-2032)
  6. 8.3 Europe Neuroendocrine Carcinoma Market Size by Application
  7. 8.3.1 Europe Neuroendocrine Carcinoma Market Size by Application (2021-2026)
  8. 8.3.2 Europe Neuroendocrine Carcinoma Market Size by Application (2027-2032)
  9. 8.3.3 Europe Neuroendocrine Carcinoma Market Share by Application (2021-2032)
  10. 8.4 Europe Neuroendocrine Carcinoma Market Size by Country
  11. 8.4.1 Europe Neuroendocrine Carcinoma Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Neuroendocrine Carcinoma Market Size by Country (2021-2026)
  13. 8.4.3 Europe Neuroendocrine Carcinoma Market Size by Country (2027-2032)
  14. 8.4.4 Europe Neuroendocrine Carcinoma Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Neuroendocrine Carcinoma Market Size (2021-2032)
  2. 9.2 China Neuroendocrine Carcinoma Market Size by Type
  3. 9.2.1 China Neuroendocrine Carcinoma Market Size by Type (2021-2026)
  4. 9.2.2 China Neuroendocrine Carcinoma Market Size by Type (2027-2032)
  5. 9.2.3 China Neuroendocrine Carcinoma Market Share by Type (2021-2032)
  6. 9.3 China Neuroendocrine Carcinoma Market Size by Application
  7. 9.3.1 China Neuroendocrine Carcinoma Market Size by Application (2021-2026)
  8. 9.3.2 China Neuroendocrine Carcinoma Market Size by Application (2027-2032)
  9. 9.3.3 China Neuroendocrine Carcinoma Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Neuroendocrine Carcinoma Market Size (2021-2032)
  2. 10.2 Asia Neuroendocrine Carcinoma Market Size by Type
  3. 10.2.1 Asia Neuroendocrine Carcinoma Market Size by Type (2021-2026)
  4. 10.2.2 Asia Neuroendocrine Carcinoma Market Size by Type (2027-2032)
  5. 10.2.3 Asia Neuroendocrine Carcinoma Market Share by Type (2021-2032)
  6. 10.3 Asia Neuroendocrine Carcinoma Market Size by Application
  7. 10.3.1 Asia Neuroendocrine Carcinoma Market Size by Application (2021-2026)
  8. 10.3.2 Asia Neuroendocrine Carcinoma Market Size by Application (2027-2032)
  9. 10.3.3 Asia Neuroendocrine Carcinoma Market Share by Application (2021-2032)
  10. 10.4 Asia Neuroendocrine Carcinoma Market Size by Country
  11. 10.4.1 Asia Neuroendocrine Carcinoma Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Neuroendocrine Carcinoma Market Size by Country (2021-2026)
  13. 10.4.3 Asia Neuroendocrine Carcinoma Market Size by Country (2027-2032)
  14. 10.4.4 Asia Neuroendocrine Carcinoma Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Neuroendocrine Carcinoma Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Neuroendocrine Carcinoma Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Neuroendocrine Carcinoma Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Neuroendocrine Carcinoma Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Neuroendocrine Carcinoma Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Neuroendocrine Carcinoma Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Neuroendocrine Carcinoma Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Neuroendocrine Carcinoma Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Neuroendocrine Carcinoma Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Neuroendocrine Carcinoma Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Neuroendocrine Carcinoma Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Neuroendocrine Carcinoma Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Neuroendocrine Carcinoma Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Neuroendocrine Carcinoma Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst